发明授权
US08222270B2 2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod
有权
用2.5％咪喹莫特配制的药物组合物治疗光化性角化病的2×2×2周治疗方案
- 专利标题： 2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod
- 专利标题（中）： 用2.5％咪喹莫特配制的药物组合物治疗光化性角化病的2×2×2周治疗方案
-
申请号： US13179315申请日： 2011-07-08
-
公开(公告)号： US08222270B2公开(公告)日： 2012-07-17
- 发明人: Michael T. Nordsiek , Sharon F. Levy , James H. Lee , James H. Kulp , Kodumudi S. Balaji , Tze-Chiang Meng , Jason J. Wu , Valyn S. Bahm , Robert Babilon
- 申请人： Michael T. Nordsiek , Sharon F. Levy , James H. Lee , James H. Kulp , Kodumudi S. Balaji , Tze-Chiang Meng , Jason J. Wu , Valyn S. Bahm , Robert Babilon
- 申请人地址： US AZ Scottsdale
- 专利权人： Medicis Pharmaceutical Corporation
- 当前专利权人： Medicis Pharmaceutical Corporation
- 当前专利权人地址： US AZ Scottsdale
- 代理商 Len S. Smith; Marlan D. Walker
- 主分类号： A01N43/42
- IPC分类号： A01N43/42 ; A01N43/52
摘要：
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available ALDARA 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for ALDARA 5% imiquimod cream to treat actinic keratosis are also disclosed and described.